Psoriasis, Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
The results of this study are not yet available.
Your participation could last up to 3 years and include 24 visits (plus additional follow up visits) to the study center
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must present with an established diagnosis of active psoriatic arthritis (PsA) for at least 6 months. Active PsA is defined as the presence of at least 3 tender joints and at least 3 swollen joints
Participant must have active psoriatic skin lesion(s) or a history of plaque psoriasis (Ps)
Participant must have been treated with 1 or more conventional disease-modifying antirheumatic drugs (cDMARDs), but must not be currently using more than one cDMARDs
Participant must agree to use a reliable method of birth control or remain abstinent during the study. Females must also remain abstinent for at least 12 weeks after stopping treatment
Participant must not be currently using any biologic agents for treatment of Ps or PsA
Participant must not have a diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
Female participant must not be breastfeeding or nursing